Rudolf Likar1, Markus Köstenberger2, Gerhard Nahler3. 1. Abteilung für Anästhesiologie und Intensivmedizin, Klinikum Klagenfurt am Wörthersee, Feschnigstraße 11, 9020, Klagenfurt am Wörthersee, Österreich. 2. Abteilung für Anästhesiologie und Intensivmedizin, Klinikum Klagenfurt am Wörthersee, Feschnigstraße 11, 9020, Klagenfurt am Wörthersee, Österreich. markus.koestenberger@kabeg.at. 3. CIS Clinical Investigation Support GmbH, Wien, Österreich.
Abstract
BACKGROUND: Cannabis was used for cancer patients as early as about 2500 years ago. Experimental studies demonstrated tumor-inhibiting activities of various cannabinoids more than 40 years ago. In view of the status of tetrahydrocannabinol (THC) as a regulated substance, non-psychotomimetic cannabidiol (CBD) is of particular importance. OBJECTIVES: Efficacy of pure CBD in various animal models as well as initial results (case reports) from patients. METHODS: Review of the literature on animal experiments and observations in humans. RESULTS: Preclinical studies, particularly recent ones, including numerous animal models of tumors, unanimously suggest the therapeutic efficacy of CBD. In isolated combination studies, synergistic effects were generally observed. In addition, CBD may potentially play a role in the palliative care of patients, especially concerning symptoms such as pain, insomnia, anxiety, and depression. Further human studies are warranted.
BACKGROUND: Cannabis was used for cancerpatients as early as about 2500 years ago. Experimental studies demonstrated tumor-inhibiting activities of various cannabinoids more than 40 years ago. In view of the status of tetrahydrocannabinol (THC) as a regulated substance, non-psychotomimetic cannabidiol (CBD) is of particular importance. OBJECTIVES: Efficacy of pure CBD in various animal models as well as initial results (case reports) from patients. METHODS: Review of the literature on animal experiments and observations in humans. RESULTS: Preclinical studies, particularly recent ones, including numerous animal models of tumors, unanimously suggest the therapeutic efficacy of CBD. In isolated combination studies, synergistic effects were generally observed. In addition, CBD may potentially play a role in the palliative care of patients, especially concerning symptoms such as pain, insomnia, anxiety, and depression. Further human studies are warranted.
Authors: Mohamad Elbaz; Mohd W Nasser; Janani Ravi; Nissar A Wani; Dinesh K Ahirwar; Helong Zhao; Steve Oghumu; Abhay R Satoskar; Konstantin Shilo; William E Carson; Ramesh K Ganju Journal: Mol Oncol Date: 2015-01-19 Impact factor: 6.603
Authors: R Ferro; A Adamska; R Lattanzio; I Mavrommati; C E Edling; S A Arifin; C A Fyffe; G Sala; L Sacchetto; G Chiorino; V De Laurenzi; M Piantelli; O J Sansom; T Maffucci; M Falasca Journal: Oncogene Date: 2018-07-30 Impact factor: 9.867
Authors: Kirsten M King; Alyssa M Myers; Ariele J Soroka-Monzo; Ronald F Tuma; Ronald J Tallarida; Ellen A Walker; Sara Jane Ward Journal: Br J Pharmacol Date: 2017-07-27 Impact factor: 8.739
Authors: P Massi; M Valenti; A Vaccani; V Gasperi; G Perletti; E Marras; F Fezza; M Maccarrone; D Parolaro Journal: J Neurochem Date: 2007-11-17 Impact factor: 5.372
Authors: Jane L Armstrong; David S Hill; Christopher S McKee; Sonia Hernandez-Tiedra; Mar Lorente; Israel Lopez-Valero; Maria Eleni Anagnostou; Fiyinfoluwa Babatunde; Marco Corazzari; Christopher P F Redfern; Guillermo Velasco; Penny E Lovat Journal: J Invest Dermatol Date: 2015-02-10 Impact factor: 8.551
Authors: Farjana Afrin; Mengna Chi; Andrew L Eamens; Ryan J Duchatel; Alicia M Douglas; Jennifer Schneider; Craig Gedye; Ameha S Woldu; Matthew D Dun Journal: Cancers (Basel) Date: 2020-04-23 Impact factor: 6.639